Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients (> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH:
History of VTE
Heart failure (NYHA class III or IV)
Indication for LMWH or UFH at therapeutic dosages
Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction)
Contraindication for the treatment with LMWH
Major surgery within the last 4 weeks; minor surgery within the last week
Thrombocytopenia (< 100.000/μl)
Prolonged prothrombin time
Prolonged activated partial thromboplastin time (aPTT)